Skip to content

A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

Solid Tumours

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Participant is an adult (according to the age of majority as defined by local regulations)
* Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
* Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
* Informed consent has been obtained from the participant or legally authorized representative, as per local regulations

Exclusion Criteria:

-Participant has a prior or current diagnosis of haematological malignancy

Lieu de l'étude

Alberta Health Services
Alberta Health Services
Calgary, Alberta
Canada

Contactez l'équipe d'étude

The Ottawa Hospital - General Campus
The Ottawa Hospital - General Campus
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
Hoffmann-La Roche
Participants recherchés
Plus d'informations
ID de l'étude: NCT04529122